Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is Unidentified Cytopenia Truly Unidentified? Or Are We Overlooking Clonality?

Medicina (Kaunas, Lithuania)·2026
Same author

The Biochemical and Genetic Effects of Lavandula angustifolia and Medical Ozone Treatments on Acute Liver Toxicity.

Biochemical genetics·2026
Same author

Segmental spinal damage predicts mobility restriction and functional decline in radiographic axial spondyloarthritis: a longitudinal study.

Rheumatology (Oxford, England)·2026
Same author

Epiregulin levels and their association with prognostic factors in Hodgkin lymphoma: a case-control study.

Annals of hematology·2026
Same author

Redundant radiography before CT in axial spondyloarthritis: high radiation burden, limited diagnostic value.

Rheumatology (Oxford, England)·2026
Same author

Investigation of the Effects of Quercetin on Early Brain Injury and Vasospazm in an Experimental Model of Subarachnoid Hemorrhage.

Turkish neurosurgery·2025

Related Experiment Video

Updated: Jun 12, 2026

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model
09:44

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Published on: March 5, 2022

Metformin plus oral contraceptive may decrease plasma sCD40 ligand in women with PCOS patients.

Levent Kebapcilar1, Ayse Gul Kebapcilar, Oktay Bilgir

  • 1Izmir Bozyaka Training and Research Hospital, Department of Internal Medicine, Izmir, Turkey. leventkebapcilar@yahoo.com

Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology
|June 10, 2010
PubMed
Summary

Polycystic ovary syndrome (PCOS) is linked to higher soluble CD40L (sCD40L) levels. Combination therapy with ethinyl oestradiol-cyproterone acetate and metformin reduced sCD40L in PCOS patients, but did not fully normalize levels compared to controls.

More Related Videos

A Modified Technique for Inducing Polycystic Ovary Syndrome in Mice
04:49

A Modified Technique for Inducing Polycystic Ovary Syndrome in Mice

Published on: July 5, 2024

Related Experiment Videos

Last Updated: Jun 12, 2026

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model
09:44

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Published on: March 5, 2022

A Modified Technique for Inducing Polycystic Ovary Syndrome in Mice
04:49

A Modified Technique for Inducing Polycystic Ovary Syndrome in Mice

Published on: July 5, 2024

Area of Science:

  • Endocrinology
  • Reproductive Medicine
  • Immunology

Background:

  • Polycystic ovary syndrome (PCOS) is a complex endocrine disorder associated with reproductive and metabolic abnormalities.
  • Elevated levels of soluble CD40 ligand (sCD40L) have been implicated in the pathophysiology of PCOS.
  • Understanding the role of sCD40L in PCOS is crucial for developing effective therapeutic strategies.

Purpose of the Study:

  • To investigate the impact of a combination therapy of ethinyl oestradiol-cyproterone acetate (EE/CA) and metformin (M) on plasma sCD40L levels in women with PCOS.
  • To compare sCD40L levels in women with PCOS before and after treatment.
  • To evaluate the normalization of sCD40L levels post-treatment in relation to healthy controls.

Main Methods:

  • A study involving 60 women diagnosed with PCOS and 30 healthy control subjects.
  • PCOS patients received a 3-month course of low-dose EE/CA oral contraceptives combined with metformin (850 mg twice daily).
  • Plasma sCD40L levels were measured in all participants before and after the 3-month treatment period.

Main Results:

  • Baseline sCD40L levels were significantly higher in women with PCOS compared to controls (p=0.002).
  • Three months of EE/CA-M therapy resulted in a significant reduction in sCD40L levels in the PCOS group (p=0.026).
  • Despite treatment, sCD40L levels in the PCOS group remained significantly higher than those in healthy controls post-treatment (p=0.039).

Conclusions:

  • PCOS is characterized by elevated sCD40L levels.
  • The addition of metformin to EE/CA oral contraceptives can decrease sCD40L levels in women with PCOS.
  • While combination therapy improves sCD40L levels, normalization compared to healthy individuals is not fully achieved.